Assessing diagnostic value of microRNAs from peripheral blood mononuclear cells and extracellular vesicles in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. — CFSMEATLAS
Assessing diagnostic value of microRNAs from peripheral blood mononuclear cells and extracellular vesicles in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome.
Almenar-Pérez, Eloy, Sarría, Leonor, Nathanson, Lubov et al. · Scientific reports · 2020 · DOI
Quick Summary
This study looked for biological markers (tiny genetic molecules called microRNAs) in blood samples from severely ill ME/CFS patients that could help doctors diagnose the disease. Researchers found that certain microRNAs and physical characteristics of particles in the blood appeared different in ME/CFS patients compared to healthy controls. If validated in larger studies, these findings could eventually lead to a simple blood test for diagnosis.
Why It Matters
ME/CFS currently lacks disease-specific biomarkers, making diagnosis difficult and delayed. This research represents progress toward an objective blood test that could accelerate diagnosis and reduce the suffering caused by diagnostic odysseys. Identifying biological mechanisms through microRNA analysis also advances understanding of ME/CFS pathophysiology.
Observed Findings
Specific microRNAs in PBMCs and extracellular vesicles showed significantly altered expression in severe ME/CFS patients compared to controls
Plasma extracellular vesicle characteristics (particle counts, size distribution, and zeta-potential) differed significantly between groups
Creatine kinase blood levels were elevated and associated with severe ME/CFS
Gene enrichment analysis indicated dysregulation of epigenetic and neuroimmune regulatory pathways
A limited set of variables showed potential discriminatory power for disease classification
Inferred Conclusions
MicroRNA profiles from both PBMCs and extracellular vesicles show promise as diagnostic biomarkers for severe ME/CFS
Extracellular vesicles in plasma may be particularly valuable for diagnostic purposes due to their accessibility and physical characteristics
The dysregulated pathways suggest neuroimmune and epigenetic dysfunction is central to ME/CFS pathophysiology
A cost-effective, targeted biomarker approach using selected miRNAs and EV characteristics warrants validation in larger populations
Remaining Questions
Do these microRNA signatures and EV characteristics extend to mild and moderate ME/CFS cases, or are they specific to severe disease?
What This Study Does Not Prove
This study does not prove that microRNAs cause ME/CFS—only that they are associated with the disease. The findings require validation in independent patient populations before any clinical diagnostic test can be developed or recommended. The study also does not establish whether these biomarkers differ in mild-to-moderate ME/CFS or how they change over disease course.